Department of Pharmacy, College of Medicine and Health Sciences, Ambo University, Ambo, Ethiopia.
Department of Pharmacy, College of Medicine and Health Sciences, Bule Hora University, Bule Hora, Ethiopia.
Vasc Health Risk Manag. 2021 Jan 5;16:591-604. doi: 10.2147/VHRM.S287465. eCollection 2020.
Stroke is becoming a leading cause of death and adult disability in the developing world.
The objective of the study was to assess the clinical characteristics, treatment outcomes, and its predictors among stroke patients admitted to Ambo University Referral Hospital (AURH), West Ethiopia.
All 111 stroke patients hospitalized from April 2016 to May 2019 were included using a hospital-based retrospective study. Socio-demographic profile, past medication history, clinical presentation, drugs prescribed for comorbid condition and stroke treatment, and outcomes data were collected using data abstraction formats and results were summarized using both descriptive and inferential statistics.
According to WHO clinical criteria, 89 (80.2%) were diagnosed with ischemic stroke, and 20 (18.0%) were diagnosed with hemorrhagic stroke. The majority of the patients 94 (84.7%) had at least one antecedent risk factor in which hypertension accounted for 44.1%. More than half, 69 (62.2%), of hospitalized stroke patients had good treatment outcomes while 42 (37.8%) had a poor outcome. The overall case-fatality rate was 18 (16.2%), 12 (13.5%) from ischemic stroke, and 6 (30.0%) from hemorrhagic stroke. Acetyl salicylic acid (ASA) with atorvastatin/simvastatin, 67 (73.5%) in ischemic stroke and 12 (60.0%) in hemorrhagic stroke, was the most frequent medications prescribed for stroke during admission while it was frequently prescribed for 48 (53.6%) of ischemic stroke and 10 (50.0%) of the hemorrhagic stroke on discharge. Overall, ceftriaxone + metronidazole 32 (28.8%) was frequently prescribed concomitant medications during admission. The major predictors identified for poor stroke outcomes were substance abuse (AOR=2.839, P=0.024) and have had not received any medication for stroke treatment during admission (AOR=12.503, P≤0.001).
A significant number of the admitted stroke patients had poor treatment outcome in which the case-fatality rate was relatively high. Substance abuse and having not received medication for stroke were the significant predictors for poor treatment outcome. Hence, a well-established stroke unit setup at AURH is required for accurate diagnosis and management of stroke to overcome stroke-related mortality and/or poor treatment outcome.
中风在发展中国家正成为导致死亡和成年人残疾的主要原因。
本研究旨在评估埃塞俄比亚西部安博大学转诊医院(AURH)收治的中风患者的临床特征、治疗结果及其预测因素。
采用医院回顾性研究,纳入 2016 年 4 月至 2019 年 5 月期间住院的 111 名中风患者。使用数据提取格式收集社会人口统计学特征、既往用药史、临床表现、合并症和中风治疗药物,并使用描述性和推断性统计方法总结结果。
根据世界卫生组织临床标准,89 例(80.2%)诊断为缺血性中风,20 例(18.0%)诊断为出血性中风。大多数患者(84.7%)有至少一个既往危险因素,其中高血压占 44.1%。69 例(62.2%)住院中风患者治疗效果良好,42 例(37.8%)治疗效果不佳。总的病死率为 18%(16.2%),缺血性中风 12 例(13.5%),出血性中风 6 例(30.0%)。住院期间,最常开的中风药物是乙酰水杨酸(ASA)联合阿托伐他汀/辛伐他汀,在缺血性中风中为 67 例(73.5%),在出血性中风中为 12 例(60.0%),而在出院时,最常开的中风药物是 ASA 联合阿托伐他汀/辛伐他汀,在缺血性中风中为 48 例(53.6%),在出血性中风中为 10 例(50.0%)。总的来说,住院期间最常开的联合用药是头孢曲松+甲硝唑,共 32 例(28.8%)。不良中风结局的主要预测因素是药物滥用(AOR=2.839,P=0.024)和住院期间未接受任何中风治疗药物(AOR=12.503,P≤0.001)。
相当数量的住院中风患者治疗效果不佳,病死率相对较高。药物滥用和未接受中风治疗药物是不良治疗结局的显著预测因素。因此,AURH 需要建立一个完善的中风单元,以便准确诊断和管理中风,从而降低与中风相关的死亡率和/或不良治疗结局。